EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): AGM/EGM
Newron announces AGM 2023 results
Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda of the AGM 2023 held today.
The agenda consisted of the approval of the balance sheet as at December 31, 2022, the appointment of the members of the Board of Directors for the financial years 2023-2025, and the determination of the renumeration of the Board of Directors.
Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We thank all our shareholders for their ongoing and longstanding support and trust”. He added: “On behalf of the Board and the Management Team, I also thank J. Donald (Don) deBethizy for his many valuable contributions to our company and his innovative thinking as member of the Board of Directors since 2014, most notably as Chairman of the R&D committee. At the same time, we welcome Gillian Dines as newly elected Board member and Chairwoman of the R&D committee. We are looking forward to working with her and are convinced that her profound R&D knowledge and entrepreneurial personality will be an asset to Newron”.
About Newron Pharmaceuticals
For more information, please contact:
18.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
1610291 18.04.2023 CET/CEST